Clinical Trials Logo

Breast Cancer clinical trials

View clinical trials related to Breast Cancer.

Filter by:
  • Not yet recruiting  
  • Page 1 ·  Next »

NCT ID: NCT05440149 Not yet recruiting - Breast Cancer Clinical Trials

The Postoperative Radiotherapy in N1 Breast Cancer Patients

PORT-N1
Start date: September 1, 2022
Phase: Phase 3
Study type: Interventional

This study is a multicenter, randomized, phase 3 clinical trial in patients with breast cancer, randomizing radiotherapy group (postmastectomy radiation therapy (PMRT)/whole breast irradiation plus regional radiotherapy (WBI+regional RT) versus and no PMRT/WBI alone group. This is a non-inferiority study aiming that there is no significant difference in the 7-year disease-free survival rate between the two groups.

NCT ID: NCT05439005 Not yet recruiting - Breast Cancer Clinical Trials

Opioid Free Versus Opioid Based Anaesthesia for Secondary Free Flap Reconstruction Surgery of the Breast: A Phase III Multicentric Randomized Controlled Study.

OFOBA
Start date: September 15, 2022
Phase: Phase 3
Study type: Interventional

This study will compare morphine consumption during the first 48 hours postoperatively between the OFA group and the CGA control group.

NCT ID: NCT05438511 Not yet recruiting - Breast Cancer Clinical Trials

A Formative Evaluation For Improving Breast Cancer Hormone Receptor Testing in Tanzania

Start date: August 2022
Phase:
Study type: Observational

The purpose of this study is to learn more about the challenges with breast cancer diagnosis in Tanzania and the support available to improve this process.

NCT ID: NCT05436808 Not yet recruiting - Breast Cancer Clinical Trials

Partial Chest Wall Radiation Therapy After Surgery for Lymph Node Negative Breast Cancer

Start date: July 2022
Phase: Early Phase 1
Study type: Interventional

The standard treatment for breast cancer when cancer cells were found near or within the margins of the tissue that is removed during breast surgery, is radiation of the entire chest wall. This may be considered overtreatment since the only reason for doing so is that cancer cells were near or in the margins of the breast tissue that was removed. In this study, the amount of radiation treatment will be limited to the area where the remaining cancer cells were found after surgery. The purpose of this study is to find out if partial chest wall radiation therapy is as good as whole chest wall radiation therapy in reducing the risk of breast cancer cancer coming back.

NCT ID: NCT05433480 Not yet recruiting - Breast Cancer Clinical Trials

A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer

Start date: June 2022
Phase: Phase 3
Study type: Interventional

This is a phase III clinical trial to evaluate the efficacy and safety of BPI-16350 in combination with Fulvestrant versus placebo combined with Fulvesrant in Patients who have HR positive and HER2 negative locally advanced´╝îrecurrent or metastatic breast cancer with disease progression following endocrine therapy.

NCT ID: NCT05431582 Not yet recruiting - Breast Cancer Clinical Trials

Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors

Start date: December 30, 2022
Phase: Phase 1
Study type: Interventional

Primary Objectives are to determine the maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D) of ZN-c3 and ZN-c3 and bevacizumab or ZN-c3 and bevacizumab plus pembrolizumab in metastatic CCNE1 amplified and TP53 mutant solid tumors as well to evaluate antitumor activity of ZN-c3 and bevacizumab or ZN-c3 and bevacizumab plus pembrolizumab in metastatic CCNE1 amplified and TP53 mutant solid tumors.

NCT ID: NCT05430347 Not yet recruiting - Breast Cancer Clinical Trials

Clinical Study of Pyrotinib in Neoadjuvant Therapy of HR-positive and HER2-positive Breast Cancer

Start date: June 15, 2022
Phase: Phase 2
Study type: Interventional

Due to neoadjuvant therapy with trastuzumab and pertuzumab is less effective for HR+/HER2+ breast cancer, and the PHEDRA Clinical Study subgroup analysis showed that the addition of pyrotinib to trastuzumab more than doubled pCR rates in HR+/HER2+ patients. our research group proposed a hypothesis that pyrotinib may be more advantageous for HR+/HER2+ breast cancer. Therefore, our center intends to carry out a multi-center, randomized controlled, prospective clinical study to compare the efficacy of pyrotinib or pertuzumab combined with docetaxel, carboplatin and trastuzumab in neoadjuvant therapy for patients with HR+/HER2+ breast cancer, and to conduct a comparative study on the safety.

NCT ID: NCT05429866 Not yet recruiting - Breast Cancer Clinical Trials

Immunological Variables Associated to ICI Toxicity in Cancer Patients

Start date: July 1, 2022
Phase: Phase 2
Study type: Interventional

This is a monocentric, prospective, pilot study that will enrol 435 subjects with solid tumours that are treated with immune checkpoint inhibitor(s) (ICI) alone or in combination with chemotherapy or targeted therapy. For enrolled subjects, clinical and laboratory evaluations will be performed and reported at different time points: - Early (4-6 weeks after treatment start) - Midtime (8-11 weeks after treatment start) - Late (13-18 weeks after treatment start) - At the occurrence of immune-related adverse events (irAEs), clinical and laboratory evaluation will be performed at two principal time points: - For the 1st time of any grade 1 or 2 irAE if the subject developed it. - For the 1st time of any grade 3 or 4 irAE if the subject developed it.

NCT ID: NCT05429814 Not yet recruiting - Breast Cancer Clinical Trials

Topical Menthol Application in Chemotherapy-Related Peripheral Neuropathy in Patients With Breast Cancer

Start date: July 1, 2022
Phase: N/A
Study type: Interventional

Peripheral neuropathy resulting from chemotherapy is a problem that concerns not only the individual but also their relatives and all healthcare personnel responsible for care. Studies to be carried out in this area are important in terms of providing evidence for nurses' practices and supporting the individual by alleviating the symptoms of the disease. Based on this information, the aim of this study is to determine the effect of menthol application, which will be applied to the hands and feet of breast cancer patients receiving chemotherapy, on CIPN.

NCT ID: NCT05428709 Not yet recruiting - Breast Cancer Clinical Trials

Women In Steady Exercise Research - Window of Opportunity for Exercise and Tumor Biology

WISER-WIN
Start date: July 2022
Phase: N/A
Study type: Interventional

The primary aim is to examine changes in tumor perfusion, oxygen saturation, and tumor physiology before and following acute physical activity in breast cancer patients. The secondary aim is to examine changes in circulating tumor DNA (ctDNA) levels before and following acute physical activity in breast cancer patients. The tertiary aim is to explore changes in circulating exerkines (cytokines and growth factors altered by exercise) before and following acute physical activity in breast cancer patients.